NYSEAMERICAN:IBIOIbio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ibio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.32 +0.12 (+5.45 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$2.18Now: $2.32▼$2.3550-Day Range N/A52-Week Range$0.05Now: $2.32▼$3.40Volume11.07 million shsAverage Volume20.82 million shsMarket Capitalization$274.60 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingIbio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.55, Ibio has a potential upside of 9.9% from its current price of $2.32.Amount of Analyst CoverageIbio has only been the subject of 1 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesIbio has received 159 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIbio has received 95 “underperform” votes. (Add your “underperform” vote.)Community SentimentIbio has received 62.60% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ibio and other stocks. Vote “Outperform” if you believe IBIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIbio does not currently pay a dividend.Dividend GrowthIbio does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ibio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $222,172.00 in company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 1.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.92 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:IBIO Previous SymbolNASDAQ:IBIO CUSIPN/A CIK1420720 Webwww.ibioinc.com Phone+1-302-3550650Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees54 Outstanding Shares118,360,000Market Cap$274.60 million Next Earnings Date8/21/2020 (Estimated) OptionableNot Optionable AMEX:IBIO Rates by TradingView Receive IBIO News and Ratings via Email Sign-up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Ibio (NYSEAMERICAN:IBIO) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Ibio? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ibio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ibio. When is Ibio's next earnings date? Ibio is scheduled to release its next quarterly earnings announcement on Friday, August 21st 2020. View our earnings forecast for Ibio. When did Ibio's stock split? How did Ibio's stock split work? Shares of Ibio reverse split on Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 8th 2018. An investor that had 100 shares of Ibio stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for IBIO? 1 analysts have issued 12 month target prices for Ibio's stock. Their forecasts range from $2.55 to $2.55. On average, they expect Ibio's share price to reach $2.55 in the next year. This suggests a possible upside of 9.9% from the stock's current price. View analysts' price targets for Ibio. Has Ibio been receiving favorable news coverage? Media stories about IBIO stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ibio earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Ibio. Who are some of Ibio's key competitors? Some companies that are related to Ibio include iShares Diversified Alternatives Trust (ALT), TELIX Pharmaceutical (TLX), Starpharma (SPL), Silence Therapeutics (SLN), Altimmune (ALT), ProMetic Life Sciences (PLI), Pfenex (PFNX), IMV (IMV), Emblem (EMC), Medicenna Therapeutics (MDNA), Ergomed (ERGO), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), Exicure (XCUR) and OncoCyte (OCX). View all competitors. What other stocks do shareholders of Ibio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ibio investors own include Inovio Pharmaceuticals (INO), Co-Diagnostics (CODX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Novavax (NVAX), Nokia Oyj (NOK), Biocept (BIOC), FuelCell Energy (FCEL) and Gilead Sciences (GILD). Who are Ibio's key executives? Ibio's management team includes the following people: Mr. Robert B. Kay, Exec. Chairman & CEO (Age 79)Mr. Robert L. Erwin, Pres (Age 66)Mr. James P. Mullaney CPA, CPA, Chief Financial Officer (Age 48)Mr. Terence E. Ryan, Chief Scientific Officer (Age 64)Dr. Renato Lobo, Chief Medical Officer What is Ibio's stock symbol? Ibio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO." How do I buy shares of Ibio? Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ibio's stock price today? One share of IBIO stock can currently be purchased for approximately $2.32. How big of a company is Ibio? Ibio has a market capitalization of $274.60 million. Ibio employs 54 workers across the globe. What is Ibio's official website? The official website for Ibio is www.ibioinc.com. How can I contact Ibio? Ibio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at +1-302-3550650. This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
